Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.
about
Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanismsPreclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine proteaseBinding-Site Identification and Genotypic Profiling of Hepatitis C Virus Polymerase InhibitorsHepatitis C Viral NS3-4A Protease Activity Is Enhanced by the NS3 HelicaseMechanism and Specificity of a Symmetrical Benzimidazolephenylcarboxamide Helicase InhibitorMolecular Mechanism by Which a Potent Hepatitis C Virus NS3-NS4A Protease Inhibitor Overcomes Emergence of ResistanceA time-resolved fluorescence-resonance energy transfer assay for identifying inhibitors of hepatitis C virus core dimerization.Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virusPrimuline derivatives that mimic RNA to stimulate hepatitis C virus NS3 helicase-catalyzed ATP hydrolysis.Double-stranded DNA and double-stranded RNA induce a common antiviral signaling pathway in human cells.Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6Challenges and successes in developing new therapies for hepatitis C.The therapeutic potential of NS3 protease inhibitors in HCV infection.Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients.New treatment strategies against hepatitis C viral infection.Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.Over-expression and characterization of NS3 and NS5A of Hepatitis C virus genotype 3a.Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends.Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects.Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A proteaseIn vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335.Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches.The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.Mathematical model for suppression of subgenomic hepatitis C virus RNA replication in cell culture.
P2860
Q24548483-E8E02E12-3B1D-481B-A9A0-FD76DD929CACQ27473126-A2C67A39-7E6B-434A-8801-7CCF021F3E9EQ27480926-F85AA3F1-45E0-4A7E-95E5-63E037660157Q27487110-B74170EB-C7D3-407E-9E58-C6C45013FEFBQ27491015-317B6716-D2B7-4AD6-ADBF-41331AEDF123Q27675615-3C145B32-A9F0-4DAA-9B35-B123B49C0D80Q33520822-1681CDBB-9E60-4386-8644-7D7392CC9E61Q33826766-4C91AB9B-C667-4624-934F-5505F71BD192Q34489239-63D7015E-D22B-47E5-8D9D-EEB5E2FE7CBBQ34545969-3A85638E-AA4A-4DD2-B9AF-DFD89682D11FQ34736874-B5AEC19B-C267-49E8-B75C-A3E5BDE9C5D1Q35829210-10B70808-36B4-460D-946C-96767E08B331Q35867385-D7F823A7-9BCC-4CBA-94C3-446AD0DA32A7Q35917596-954F654B-0425-41BB-A4AB-3EEA0081044AQ36233823-BFDF1363-E680-4D76-BCFF-26A0EDCC0C06Q36249891-635F52A5-AAF2-4B45-A1C8-059D31D2C323Q36276835-BB872189-4448-4FF9-9C81-D4C4B4A3AFDDQ36384127-DAECEEAA-3882-40ED-A55B-A4AA23C5B1FBQ36655935-D733F997-110D-4720-8259-A3E65257FBB5Q36667066-F2FDD192-C288-4967-A9C5-4BCC7802CB10Q37348347-C2991B97-60F5-4332-BFC8-692C48787A00Q37855863-C4C137FC-0266-467F-BE4D-5BF829541F83Q37990840-4B3412F9-1280-4D0F-BD79-5373F34BBEB5Q38699377-080FF115-B6E5-48E0-B176-114BCE21B55FQ39658512-E0075C87-6205-489D-ACE8-D775A382B0DEQ40327697-F6D7B008-BA0F-4563-A3BF-E9C85543D7FAQ42205040-FA16ACF3-8401-4C83-805D-F805260F91E8Q42991856-E6DC5BBC-3BB6-44BF-A225-1A20702ABF60Q43039356-20C158FB-48E2-45C8-8D54-2217C4C185CC
P2860
Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Sensitivity of NS3 serine prot ...... 3 to the inhibitor BILN 2061.
@en
type
label
Sensitivity of NS3 serine prot ...... 3 to the inhibitor BILN 2061.
@en
prefLabel
Sensitivity of NS3 serine prot ...... 3 to the inhibitor BILN 2061.
@en
P2093
P2860
P1433
P1476
Sensitivity of NS3 serine prot ...... 3 to the inhibitor BILN 2061.
@en
P2093
Christiane Bousquet
Daniel Lamarre
Diane Thibeault
Lisette Lagacé
Peter W White
Rock Gingras
Roger Maurice
P2860
P304
P356
10.1128/JVI.78.14.7352-7359.2004
P407
P577
2004-07-01T00:00:00Z